Fig. 5
GABRA1 is targeted by miR-181a-5p. A the binding site and mutation sequence between miR-181a-5p and GABRA1; B–C qRT-PCR and western blot to detect the levels of GABRA1 mRNA and the encoded protein GABAARα1, respectively, in patients with OA (B) and the mouse model of OA (C); D–E the binding between miR-181a-5p and GABRA1 tested by RNA pull-down (D) and dual-luciferase reporter gene (E) assays; F the levels of GABRA1 mRNA and the encoded protein GABAARα1 assessed by qRT-PCR and western blot, respectively, after transfection of miR-181a-5p inhibitor in chondrocytes induced by IL-1β. Data were expressed as mean ± standard deviation. N = 20 for clinical experiments, and N = 10 mice/group for animal experiments. Cell experiments were repeated 3 times. *P < 0.05, compared with control, sham, or mimic NC group; #P < 0.05, compared with the NC-probe or 1L-1β + inhibitor NC group